Zacks Investment Research
16 Jun 2026, 13:51 UTC · 1h ago
Beam Therapeutics Stock Soars 21% in Three Months: Here's Why
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
16 Jun 2026, 13:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Beam Therapeutics' BEAM-302 candidate for AATD showed durable increases in functional AAT levels and a favorable safety profile in a phase I/II study. — Positive clinical data for a lead pipeline candidate is a primary driver of biotech valuation and risk appetite.
+0.60Beam Therapeutics plans to pursue an accelerated approval pathway for BEAM-302, with a global cohort initiation expected in H2 2026. — Accelerated approval pathways reduce the time to commercialization, increasing the net present value of the asset.
+0.40The company is on track to submit a Biologics License Application (BLA) for its sickle cell disease therapy, risto-cel, by the end of 2026. — A concrete timeline for a BLA submission provides a clear catalyst for future stock price movement.
+0.30Continue reading
6 related stories
Search tags
Beam Therapeutics is developing BEAM-301 for glycogen storage disease type 1a in a phase I/II dose-exploration study. — Pipeline expansion into new indications diversifies the company's risk profile, though early-stage data is less impactful than late-stage.
+0.20Which stocks this story touches
Shares rose 21% driven by positive clinical developments and encouraging data for BEAM-302.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
9h ago
